CUSIP: 10567X101 | NYSE | 7 institutional holders
5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.
| Holder | Shares | % of Class | Change | Event Date | vs 13F |
|---|---|---|---|---|---|
| 13GJiangsu Hengrui Pharmaceuticals Co., Ltd. | 7,420,091 | 8.2% | New 5%+ stake | Sep 30, 2026 | No 13F filer matched |
| 13D/AOrbimed Advisors LLC with OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC |
| Style | Turnover | Location | Filed | ||||
|---|---|---|---|---|---|---|---|
| 7,585,769 | $153.2M | 0.0% | Growth | Medium | Boston, MA | 2026-11-10 | |
| 288,798 | $5.8M | 0.0% | Index | Very Low | Boston, MA | 2026-11-06 | |
| 229,072 | $4.6M | 0.0% | Core | Medium | Zurich, Switzerland | 2026-11-10 | |
| 40,282 | $813.7K | 0.0% | Core | Very High | New York, NY | 2026-11-09 | |
| 36,109 | $729.4K | 0.1% | ETF | Low | Yakima, WA | 2026-10-29 | |
| 919 | $18.6K | 0.0% | Core | Medium | New York, NY | 2026-11-04 | |
| 10 | $202 | 0.0% | Growth | Low | Tokyo, Mexico | 2026-10-22 |
| 13.5% |
| Unchanged |
| Sep 8, 2026 |
| Not yet in a 13F |
| 13DAH Bio Fund IV, L.P. | 10,232,420 | 11.4% | New 5%+ stake | Aug 7, 2026 | No 13F filer matched |
| 13GFrazier Life Sciences Public Fund, L.P. with Fhmls XII, L.L.C., Frazier Life Sciences XII, L.P., Fhmls XII, L.P., +3 more | 4,976,457 | 5.5% | New 5%+ stake | Aug 7, 2026 | No 13F filer matched |